Novo Nordisk won't increase Metsera bid, defends antitrust compliance
MLex Summary: Novo Nordisk said it will not increase its offer for US biotech Metsera. "We believe that the structure of our potential merger agreement is compliant with antitrust laws," the...To view the full article, register now.
Already a subscriber? Click here to view full article